Immune boosters take on brain cancer: new trial launches

NCT ID NCT06816927

Recruiting now Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, in people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 92 participants will receive the drugs before and after surgery to see if they are safe and help the immune system attack the tumor. The goal is to find a better way to control this aggressive disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and relatlimab (immunotherapy drugs)
What this could lead to: If successful, this could lead to a new treatment option that helps control glioblastoma by boosting the immune system's ability to attack the tumor.
What could go wrong: This is an early-phase trial with only 92 participants, so results may not apply to all patients. Immunotherapy can cause serious side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEWLY DIAGNOSED GLIOBLASTOMA

Contacts and locations

Locations

Duke University
RECRUITING

Durham, North Carolina, 27750, United States
Peter MacCallum Cancer Centre
RECRUITING

Parkville, Victoria, 3000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.